Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATYR1940 multiple ascending dose study in adults with facioscapulohumeral muscular dystrophy
NL-OMON42284Active, not recruiting
- Sponsor
- aTyr Pharma
- Start
- Oct 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial in facioscapulohumeral muscular dystrophy (FSHD) comparing ATYR1940 with Placebo (2 arms). Primary endpoints: Safety and tolerability, Pharmacokinetics and 1 more. Started Oct 2014; status: active, not recruiting.
02
Drugs
Resolaris
03
Conditions
facioscapulohumeral muscular dystrophy (FSHD)
Beyond the preview
Go deeper on NL-OMON42284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42284.